Header cover image

Australian Biotech Breakthroughs

Results

4

1 new

Biotech stocks worldwide which are expected to become profitable in the next 3 years.

4 companies

Mesoblast

Market Cap: AU$2.9b

Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.

MSB

AU$2.24

7D

-7.1%

1Y

-11.1%

Immutep

Market Cap: AU$567.4m

A biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.

New

IMM

AU$0.39

7D

-2.5%

1Y

24.2%

Aroa Biosurgery

Market Cap: AU$231.5m

Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.

ARX

AU$0.67

7D

-4.3%

1Y

25.2%

Paradigm Biopharmaceuticals

Market Cap: AU$114.2m

Engages in the research and development of therapeutic products for human use in Australia.

PAR

AU$0.26

7D

-7.1%

1Y

-46.9%